Sign in
Stories
Stem Cell Therapy and Public Offerings
Share
Advancements in Cancer Treatment and Mar...
Aphea.Bio Secures €70M Funding for Susta...
Bavarian Nordic's Vaccine Transformation
4P-Pharma Secures €15 Million Funding
AB Science's Medical Breakthrough Webcas...
ABBio Innovates Antibody Development
Overview
API
Animal stem cell therapy market is projected to expand at a 5.2% CAGR, reaching a valuation of around US$ 437.3 Mn by 2032. ArriVent BioPharma and Sagimet Biosciences announce pricing of public offerings, with ArriVent raising $175.0 million and Sagimet $112.5 million, respectively.
Ask a question
How might the expansion of the animal stem cell therapy market impact the veterinary care industry and the development of advanced veterinary care options?
What are the potential implications of Sagimet's denifanstat, a selective FASN inhibitor, for the treatment of NASH?
What factors contribute to the growing interest in public offerings in the biopharmaceutical industry, and how do these offerings impact the companies involved?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Oct 2023
Nov 2023
Dec 2023
Jan 2024
Coverage